Biosimilars: A Multidisciplinary Perspective  by Khraishi, Majed et al.
Clinical Therapeutics/Volume 38, Number 5, 2016
CommentaryBiosimilars: A Multidisciplinary PerspectiveMajed Khraishi, MB, BCh, FRCPC1; David Stead, GPhC, MRPharmS, DMS2;
Milan Lukas, MD, PhD3; Florian Scotte, MD, PhD4; and Holger Schmid, MD, MSc5
1Clinical Professor of Medicine (Rheumatology), Memorial University of Newfoundland, Canada; 2Recently
retired Medicines Procurement Specialist Pharmacist NHS South West and past Chairman of
Pharmaceutical Market Support Group; 3IBD Clinical and Research Center, And 1st Medical Faculty,
Charles University, Prague, Czech Republic; 4Medical Oncology and Supportive Care in Cancer Unit
Georges Pompidou European Hospital, Paris, France; and 5Clinic and Policlinic IV, Section of Nephrology,
Munich University Hospital, Campus Innenstadt, Munich, GermanyAccepted for publication February 22, 2016.
http://dx.doi.org/10.1016/j.clinthera.2016.02.023
0149-2918/$ - see front matter
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ABSTRACT
A biosimilar is an ofﬁcially regulated and approved
copy of an originator biologic therapy. Improved afford-
ability and consequent wider patient access compared
with biologics are a signiﬁcant appeal of biosimilars.
Regulatory guidelines for biosimilar development and
approval are rigorous and undergoing constant reﬁne-
ment. The process of licensing approval for all biosimi-
lars requires demonstration of comparability in quality,
efﬁcacy, and safety between the biosimilar and reference
(originator) product, which is undertaken in a stepwise
procedure of nonclinical and clinical evaluation. The
approval of 420 biosimilars in Europe in several drug
classes, including the ﬁrst monoclonal antibody biosimi-
lar, bears testimony to the increasing regulatory accept-
ance of these agents. In contrast, the clinical application
of biosimilars remains underrecognized by physicians
across therapy areas. Therefore, this article aims to
provide a comprehensive review of the biosimilar devel-
opment process and to provide multidisciplinary guid-
ance on the potential therapeutic utility of biosimilars in
clinical practice. Speciﬁcally, experts discuss clinical
developments in the introduction of biosimilars across
the disciplines of gastroenterology, nephrology, oncol-
ogy, and rheumatology, and from a payer perspective,
and also highlight a common need for ongoing pharma-
covigilance, robust head-to-head clinical studies, and
real-world data to establish the long-term risk-beneﬁt
proﬁle of biosimilars. In conclusion, signiﬁcant potential
exists for biosimilars to revolutionize biologic therapy by
widening patient access across therapy areas. (Clin Ther.
2016;38:1238–1249) & 2016 The Authors. Published by
Elsevier HS Journals, Inc.1238Key words: biosimilars, pharmacovigilance, safety,
arthritis, Inﬂammatory Bowl Disease (IBD), Nephrology.INTRODUCTION
The success of biologic therapies and impending patent
expiry for many of these agents heralded the introduc-
tion of biologic similars (biosimilars), which have gained
increasing acceptance since the ﬁrst European Medicines
Agency (EMA) approval of a somatropin biosimilar in
2006.1 In early 2015, 20 biosimilars were approved in
Europe (Table I), whereas a ﬁlgrastim biosimilar was
approved by the US Food and Drug Administration
(FDA) after a recommendation from the US Oncologic
Drugs Advisory Committee.2 Despite increasing accep-
tance from a regulatory perspective, biosimilars remain
underrecognized by treating physicians.3 Therefore, the
overarching aims of this article were to review the bio-
similar development process and to provide guidance,
from a multidisciplinary perspective, regarding the use of
biosimilars in clinical practice.WHAT IS A BIOSIMILAR?
Unlike small-molecule chemical agents, biologic therapies
are proteins or peptides that have been developed using
recombinant DNA technology in living systems andVolume 38 Number 5
Table I. EMA-approved biosimilars.1,5,58,59,*
INN (Molecule) Product Name Therapy Area Approval Date
Epoetin alfa (HX575) Abseamed Chemotherapy-induced anemia August 2007
Epoetin alfa Hexal Anemia associated with CKD†
Binocrit Increasing yield during planned
autologous blood transfusion
Epoetin zeta (SB309) Silapo Chemotherapy-induced anemia December 2007
Retacrit Anemia associated with CKD‡
Increasing yield during planned
autologous blood transfusion
Filgrastim (XM02,
EP2006, PLD108)
Biogastrim Cancer September 2008
Ratiogastrim Hematopoietic stem-cell transplantation
Tevagrastim Neutropenia
Zarzio February 2009
Filgrastim Hexal
Filgrastim
ratiopharm
September 2008
Withdrawn April 2011
Nivestim June 2010
Grastoﬁl Neutropenia October 2013
Accoﬁl September 2014
Follitropin alfa Bemfola Anovulation (IVF) March 2014
Inﬂiximab (CT-P13) Inﬂectra Ankylosing spondylitis September 2013
Remsima Crohn’s disease
Psoriatic arthritis
Psoriasis
Rheumatoid arthritis
Ulcerative colitis
Somatropin Omnitrope Pituitary dwarﬁsm April 2006
Prader-Willi syndrome
Turner syndrome
Valtropin Pituitary dwarﬁsm April 2006
Turner syndrome Withdrawn May 2012
Somatropin
Biopartners
Growth hormone deﬁciency August 2013
CKD ¼ chronic kidney disease; EMA ¼ European Medicines Agency; INN ¼ international nonproprietary name; IVF ¼
in vitro fertilization.
*Discussion of biosimilars targeted toward endocrinologic disorders is beyond the scope of this multidisciplinary article,
which did not include an endocrinology specialist among the expert panel of authors.
†Licensed for intravenous administration.
‡Licensed for intravenous and subcutaneous administration.
M. Khraishi et al.extracted via complex puriﬁcation techniques.1,4 There-
fore, the structural and manufacturing complexity of
biologic therapies and the requirement for proprietary
knowledge preclude duplication, whereas the simplerMay 2016structures of small-molecule products and the ability to
replicate the patented production process have facilitated
development of generic versions, which are identical
copies of the originator.5 Thus, biosimilar refers to a1239
Clinical Therapeuticsproduct that is similar (but not identical) to the originator
biologic therapy.4 In the United States and Canada,
biosimilars are also known as follow-on biologics and
subsequent entry biologics, respectively.6DEVELOPMENT PROCESS FOR BIOSIMILARS
Due to the relatively recent introduction of biosimilars,
the process by which these agents are tested and approved
is continuously being updated and reﬁned.4 Regulatory
authorities including the European Medicines Agency
(EMA), US Food and Drug Administration (FDA), and
the World Health Organization have adopted unique
measures for biosimilars, recognizing that the approval
process for generic medicines cannot be applied to
the licensing of biosimilars (Table II).4,7 Guidance from
these organizations has been adopted as a reference for
countries worldwide, including China, India, Latin Amer-Table II. Biosimilar approval process of the EMA, FDA
EMA
Classiﬁcation of
biosimilarity
“…a biological medicinal
product that contains a
version of the active
substance of an already
authorized original
biological medicinal
product (reference
medicinal product).”
“…that
is hig
refere
notwi
differ
inacti
that “
mean
betwe
produ
produ
safety
of the
Essential
requirements
for
conﬁrmation of
similarity with
originator
Quality characteristics,
biological activity, safety
and efﬁcacy
Safety, p
Approval system Stepwise process to compare biosimil
1. Comprehensive physicochemical an
2. Nonclinical studies
3. Clinical studies
EMA = European Medicines Agency; FDA = US Food and Drug
1240ica, and Russia.8 Key differences between countries
relate to the choice of originator and extrapolation of
indications.8 Regardless of the clinical indication, all
biosimilars are required to undergo a comparability
exercise in order to conﬁrm a high degree of similarity
with the reference product (originator) in terms of quality,
biological activity, efﬁcacy, and safety.9,10 Accordingly,
the EMA, the ﬁrst authority to establish a regulatory
framework for biosimilars, has stipulated a process of
approval that follows a stepwise procedure from detailed
physicochemical and biological characterization toward
nonclinical in vivo studies and clinical studies
(Figure 1).9,10 The framework for biosimilars was an
extension of the guidelines for comparability after man-
ufacturing changes of originator biologics.11 The EMA
and other regulatory bodies have become highly
experienced in comparability exercises, as these occur
routinely for all biologics over time. The lessons learned, and WHO.7,10,60
FDA WHO
the biological product
hly similar to the
nce product
thstanding minor
ences in clinically
ve components” and
there are no clinically
ingful differences
en the biological
ct and the reference
ct in terms of the
, purity, and potency
product.”
“A biotherapeutic product
that is similar in terms of
quality, safety and efﬁcacy
to an already licensed
reference biotherapeutic
product.”
urity, and potency Quality, safety, and efﬁcacy
ar with originator:
d biological analyses
Administration; WHO = World Health Organization.
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Comparative non-clinical
Comparative clinical studies
studies
Step 3
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Figure 1. European Medicines Agency (EMA) approval processes for originator and biosimilar development.9
The approval process for originator products requires submission of quality, preclinical, and clinical
data. The process of biosimilar approval developed by the EMA is based on demonstration
of comparability to the originator product and, similar to the originator approval process,
follows a stepwise procedure from detailed physicochemical and biological characterization to
the undertaking of nonclinical in vivo studies and clinical studies. The extent and nature of the
clinical evaluation depend on the level of evidence acquired in previous steps (in particular,
the reliability of physicochemical, biological, and nonclinical in vitro data).8,9
M. Khraishi et al.over the past 3 decades of managing the life cycle of
biologics have been applied in the past 10 years to
biosimilars. Thus, the biosimilar comparability exercise
is not a new process invented for biosimilars, rather it is
one that has been adapted from all biologics and now
applied with great rigor to biosimilars.
Once EMA approval is granted, as with all bio-
logics, manufacturers are also required to implement a
rigorous pharmacovigilance program of their biosimi-
lars within a risk-management plan to continuously
monitor for and appropriately manage safety signals.9NONCLINICAL AND CLINICAL DATA
Nonclinical (in vitro and in vivo bioanalytical, pharma-
cokinetic [PK], pharmacodynamic, and toxicological
studies) and clinical data are required to show clinical/May 2016therapeutic equivalence between the biosimilar and refer-
ence product.12 To examine the nature of nonclinical and
clinical evidence obtained, examples are drawn for
biosimilars within the anti–tumor necrosis factor-α),
erythropoiesis-stimulating agents (ESAs), and granulocyte
colony–stimulating factor drug classes (Table I).12–14
Nonclinical Testing
Extensive in vitro and in vivo investigations are
undertaken before a biosimilar enters the next clinical
evaluation step. Historically, comparability studies
were ﬁrst conducted and revealed similarity between
the epoetin biosimilars HX575 and SB309 and the
reference epoetin product (for intravenous [IV] and
subcutaneous [SC] administration).15,16 As the ﬁrst
monoclonal antibody biosimilar approved in Europe,
the inﬂiximab biosimilar CT-P13 underwent1241
Clinical Therapeuticscomprehensive nonclinical testing.13 Similarity of CT-
P13 to reference inﬂiximab was shown for molecular
structure (including primary amino acid sequence,
protein folding, and posttranslational modiﬁcations
such as glycosylation), product stability and quality,
and binding afﬁnities for soluble monomeric and
trimeric forms of tumor necrosis factor-α and trans-
membrane tumor necrosis factor-α.17 Additionally,
the PK and toxicity proﬁle of CT-P13 did not
signiﬁcantly differ from that of the reference product
when both products were administered to rats at doses
of 10 and 50 mg/kg.17
Clinical Efficacy
According to the EMA, the aims of clinical evalua-
tion are to resolve slight differences potentially arising
in previous steps of the development process and to
conﬁrm comparable clinical performance between the
biosimilar and reference products.10 In aiming to
show comparability, therapeutic equivalence is the
generally accepted design, whereby a prespeciﬁed
clinically accepted margin is appointed (and approved
by the EMA) to establish whether differences exist
between biosimilar and reference groups.12 Clinical
studies are actually conﬁrmatory only with a focus on
immunogenicity, PK equivalence, and therapeutic equi-
valence in a sensitive (previously approved) indication.
Most often, these cannot be assessed effectively in
nonclinical studies.
HX575 was deemed pharmacokinetically and phar-
macodynamically bioequivalent to the reference epoetin
based on a study in 80 healthy subjects that showed area
under the curve (AUC) for epoetin concentration and
area under the effect curves for hemoglobin (Hb) fell
within established therapeutic bioequivalence 90% CI
margins after a single IV bolus injection.18 Although a
10% reduction in HX575 exposure compared with the
reference was noted, the authors concluded that both
products were similarly efﬁcacious at steady state.12,18 In
clinical practice, the lower exposure could possibly
translate to differences in clinical response if switching
from the reference product to the biosimilar product.12
Comparable bioavailability was noted for SC and IV
administration of SB309 in 2 studies of healthy
volunteers after post hoc analyses of the 90% CI
margin for Cmax and application of a correction factor
to account for differences in protein content between
SB309 and the reference epoetin.16,19,20 Clinical studies
of HX575 and SB309 for correction of or maintenance1242therapy for renal anemia have generally shown thera-
peutic equivalence of the 2 biosimilars versus the
reference epoetin after IV administration.16,21–23
European licensing approval for CT-P13 included 2
randomized, double-blind trials: a Phase I PK study in
250 patients with ankylosing spondylitis (PLANETAS
[Program Evaluating the Autoimmune Disease Inves-
tigational Drug cT-p13 in AS Patients]) and a Phase III
efﬁcacy study in 606 patients with active rheumatoid
arthritis (RA) despite methotrexate therapy (PLAN-
ETRA [Program Evaluating the Autoimmune Disease
Investigational Drug cT-p13 in RA Patients]).13,24,25 In
PLANETAS, the primary end point was PK equivalence
between CT-P13 at steady state and the reference
inﬂiximab, which was established if the 90% CI for
the ratio of the mean for each agent was within the
margin of 80% to 125%. Similarly, equivalent efﬁcacy
for CT-P13 and reference inﬂiximab, as determined by
the American College of Rheumatology 20% response
at week 30, was the primary end point for PLAN-
ETRA.25 Results of both studies revealed geometric
means approaching 100% for plasma exposure ([AUC]
and Cmax) in patients with ankylosing spondylitis and
an American College of Rheumatology 20% treatment
difference of 2% for patients with RA, thereby
conﬁrming the PK and clinical equivalence of CT-
P13.24,25
In other product classes, comparable efﬁcacy of the
biosimilar EP2006 and reference ﬁlgrastim in PK and
pharmacodynamic studies of healthy adults as well
as a single-arm, noncomparative study in breast
cancer patients at high risk of chemotherapy-induced
neutropenia formed the basis of its EMA approval in
February 2009.4
Safety
EMA guidelines specify that the safety of a bio-
similar is assessed using parameters that are identical
to those used to evaluate the reference product and in
a large enough patient population to compare adverse
event frequencies.26 In general, clinical studies of
biosimilars have demonstrated adverse event proﬁles
that are comparable to the reference product
class.13,14,27 As for originator biologics, there are
additional safety implications, most notably related
to immunogenicity.4 Risk of immunogenicity is a
concern with any biologic therapy, with the
potential for small molecular variations to translate
to clinically signiﬁcant immunogenicity differencesVolume 38 Number 5
M. Khraishi et al.manifesting as acute anaphylaxis, serum sickness, or
antibody generation.26,28 Preclinical safety assess-
ments and risk mitigation strategies are aimed toward
characterizing biologics and therefore minimizing such
risks before clinical testing.28,29
Although cases of immunogenicity may not always
produce clinical consequences, the generation of anti-
bodies could compromise treatment efﬁcacy and/or
trigger systemic immune reactions.12 Pure red cell
aplasia (PRCA) is a serious, albeit rare, immunogenic
adverse event associated with epoetin products and
occurred at a signiﬁcantly higher incidence after a
formulation and packaging change in the epoetin alfa
reference biologic EPREX in 1998.30 It is important to
note that the lessons learned from the emergence of
PRCA with the originator product were incorporated
into the biosimilar guidelines and that since their
approval in 2007, there is no available evidence of an
increased risk of PRCA associated with the use of an
approved biosimilar epoetin in a regulated market in
the postmarketing setting.
Although existing pharmacovigilance data implied
that the background rate for PRCA for epoetin bio-
logics was approximately 1 in 100,000 patient-years,
the reporting of a case of PRCA conﬁrmed by
neutralizing antiepoetin antibodies after SC adminis-
tration in the HX575 treatment group, as well as a
second suspected case of PRCA, led to the early
termination of SWEEP (Study to Evaluate the Efﬁcacy,
Safety and Immunogenicity of Subcutaneous HX575
in the Treatment of Anemia Associated With Chronic
Kidney Disease).12,31 The SC route of administration
was thus not approved by the EMA, and HX575
remains IV administration only. This is evidence
demonstrating that the rigorous processes of biosimi-
lar testing are working reliably. Nevertheless, results
from SWEEP highlight the need for ongoing character-
ization of emerging safety issues related to biosimilar use
and underscore the fundamental importance of conti-
nued pharmacovigilance.12 Indeed, risk-management
plans for biosimilar epoetins include additional post-
marketing surveillance studies to address rare immuno-
genic events such as PRCA.4
In trials of CT-P13, the development of antidrug
antibodies in CT-PI3–treated patients was not found
to differ markedly from patients initially given refer-
ence inﬂiximab or those who switched from the
reference product to CT-P13 at the end of the ﬁrst
year of a 2-year extension study.13,24,25 Guidance hasMay 2016been issued to prohibit automatic substitution of
biosimilars, with prescribing decisions clearly assigned
to the physician.4,5
Other aspects of biosimilar development and utiliza-
tion that have implications for safety are interchange-
ability, which may allow for automatic substitution,
and switching, a decision made by a physician to
substitute a biosimilar for its reference product. Details
of these concepts have been comprehensively discussed
elsewhere.5,32 In the United States, based on guidance
from the FDA, for a biosimilar to be considered
interchangeable with its reference product, the agent
must demonstrate a capability of being switched with-
out incurring signiﬁcant safety risks (as well as reduced
efﬁcacy) at an individual patient level. Additionally, for
a product administered more than once, safety and
reduced efﬁcacy risks of switching must not be greater
than with repeated use of the reference product. Only
with an FDA-approved interchangeability designation
would automatic substitution be allowed at the phar-
macy.1 In Europe, the EMA does not provide a
deﬁnition of interchangeability, but rather leaves the
decision regarding automatic substitution to the
European Union member states. For the most part in
the European Union, country-speciﬁc laws have been
enacted that do not allow automatic substitution of
biosimilars for their reference biologics.4,5
Despite a lack of consensus on the evaluation of
interchangeability, switching was assessed in an open-
label 48-week extension of a Phase III trial of CT-P13,
and it was concluded that there were generally con-
sistent safety proﬁles between the CT-P13 group and
those who switched from the reference inﬂiximab to
CT-P13 after 54 weeks of treatment.13 After switching
from intravenously administered epoetin alfa to IV
SB309 in a head-to-head crossover trial, the mean
weekly doses of epoetin zeta and the reference epoetin
were within the established equivalence margin (92.68
and 92.58 IU/kg/wk for epoetin zeta and the reference
epoetin alfa, respectively). Similarly, mean Hb levels
were within the established margins (11.35 and 11.54
g/dL for epoetin zeta and reference epoetin alfa,
respectively), whereas minor nominal dose adjust-
ments to maintain steady Hb levels were seen between
treatment periods.23 Although potential concerns exist
regarding switching between an originator and a
biosimilar, a 2012 review found no evidence of any
relevant safety issues from clinical trial or
postmarketing surveillance data.331243
Clinical TherapeuticsExtrapolation of Data
After the rigorous comparability exercise compris-
ing both nonclinical and conﬁrmatory clinical studies,
on the basis of appropriate nonclinical scientiﬁc
justiﬁcation, a given biosimilar may be approved for
other indications for which the originator product is
licensed without the necessity for clinical data on
those indications (referred to as indication extrapola-
tion).26,34 Extrapolation may beneﬁt from a common
mechanism of action across indications.34 For
example, epoetin has a single target binding site,
whereas monoclonal antibodies have binding regions
that participate in numerous biological activities.34
However, it is important to consider that differences
in efﬁcacy and safety risk may exist between
indications.26,34 Thus, despite potential beneﬁts of
indication extrapolation (eg, cost savings and wider
patient access), a cautious approach to selection of
patient populations may be warranted, especially
where the mechanism of action may differ.26,35
There was extensive bioanalytic assessment of all
known mechanisms of action for Crohn’s disease and
ulcerative colitis, which showed in relevant nonclinical
models that CT-P13 and the originator inﬂiximab did
not differ. Based on the totality of evidence (highly
comparable physicochemical and functional charac-
teristics, equivalent pharmacokinetics and pharmaco-
dynamics, comparable immunogenicity, therapeutic
equivalence in a sensitive indication, and nonclinical
interrogation of all known mechanisms of action in
the inﬂammatory bowel disease indications), the EMA
granted extrapolation to all the indications approved
for reference inﬂiximab. As a result, in the case of
biosimilar inﬂiximab, a signiﬁcant cost reduction
enables meaningfully greater access to a critical bio-
logic therapy in patients with inﬂammatory bowel
disease (IBD), potentially earlier in the course of
their disease within the context of international
recommendations.
Pharmaeconomic Value of Biosimilars
A fundamental aim in developing biosimilars is to
improve patient outcomes by offering access to bio-
logics with improved affordability.5 Bearing in mind
that the primary purpose of biosimilar clinical study
programs is to conﬁrm comparable efﬁcacy and safety
in a sensitive patient population, the availability of
such data has nevertheless enabled the development of
cost models to ascertain the feasibility of potential cost1244savings with biosimilars compared with their reference
products. Two budget impact analyses have estimated
that the use of CT-P13 for RA treatment in selected
countries in Central and Eastern Europe (Bulgaria,
Czech Republic, Hungary, Poland, Romania, and
Slovakia or Ireland) may generate cost beneﬁts that
are 20% to 25% lower compared with the reference
inﬂiximab. The potential for cost savings is partic-
ularly pertinent for impoverished European countries
where patient access to biologics is curtailed to a
greater extent than in higher income countries.36MULTIDISCIPLINARY EXPERT PERSPECTIVES
Gastroenterology
The recent approval of inﬂiximab biosimilars for
IBD has prompted signiﬁcant debate in the ﬁeld of
gastroenterology.6,37 Physicians have been generally
unaware of the innovative licensing approach on
which the approval of biosimilars is based.3
Misunderstanding among gastroenterologists may
arise, in particular, from a heavy reliance on robust
disease-speciﬁc clinical trial data (eg, for Crohn’s
disease and UC) to gauge clinical validity as is a
prerequisite for originator therapies, but may be
superﬂuous, time-consuming, and costly in the case
of biosimilars.37 Therefore, gastroenterologists should
be aware that there is a crucial distinction between the
evaluation of originators and biosimilars in that
preclinical research involving physicochemical, PK,
and pharmacodynamic analyses drive the approval
process for biosimilars, with existing or new clinical
trials providing important supporting data. The
licensing of CT-P13 is a pertinent example of this
process, which encompassed extensive physicochem-
ical characterization based on batch-to-batch analysis,
as well as nonclinical and clinical studies and mech-
anism of action studies to conﬁrm similarity with the
originator inﬂiximab.38 This approach will expedite
the introduction of biosimilars in real-world practice.
From the perspective of the Czech Republic, the
rapid and robust reduction (30%–40%) in costs
associated with biosimilars has facilitated earlier
initiation of biologic therapy in those patients with
IBD on treatment waiting lists, with 1000 more
entering treatment in 2014 compared with the pre-
vious year. Emerging results from prospective
observational studies, including interim data from a
Hungarian nationwide cohort, support the short-termVolume 38 Number 5
M. Khraishi et al.clinical efﬁcacy and safety of CT-P13 in patients with
IBD, including those who switched from the origina-
tor inﬂiximab.39,40 Although such results are promis-
ing, implementation of national registries of IBD
patients on biologic therapy; prospective, long-term
real-world data on clinical efﬁcacy and safety; and
better dissemination of the approval process are,
among others, essential factors that will need to be
addressed if biosimilars are to gain widespread accept-
ance in gastroenterology.
Nephrology
ESA markets for treatment of chronic kidney dis-
ease–associated anemia have proven to be highly
country-speciﬁc, and even across EU countries, the
penetration rate of biosimilar epoetins varies signiﬁ-
cantly.41 The still unsatisfying acceptance of biosimilar
epoetins is multifactorial, often due to a persistent lack
of information and expertise in the ﬁeld of biological
agents. A lack of availability of biosimilar advocacy
and policies, together with the sometimes confusing
nomenclature, promotes further uncertainties.
Despite such studies as the pan-European, prospec-
tive Monitor-CKD5 (Multi-level Evaluation of Anae-
mia Treatment, Outcomes, and Determinants in
Chronic Kidney Disease Stage 5) study of HX575,42
additional large-sample, long-term observational stud-
ies are urgently needed. When reviewing the ESA class
of biological products, a recent systematic analysis of
adults with chronic kidney disease suggested that the
currently available clinical evidence was markedly less
than that of the proprietary ESAs.43 The marketing
withdrawal of peginesatide, a long-acting originator
ESA, that was recalled in February 2013 after reports
of severe hypersensitivity reactions in dialysis patients
who received a ﬁrst dose, is a warning example that
strict postmarketing surveillance is important.44 In
addition, nephrologists are encouraged to carefully
observe developments worldwide including threshold
countries, where often extensive practical experience
with biosimilar ESAs exists.31 Long-term postmarket-
ing real-world data demonstrating clinical effective-
ness, safety, and ﬁnally cost savings are required to
complete the success story of biosimilar ESAs in the
ﬁeld of nephrology.
Oncology
Use of biosimilars in oncology to date has been
largely conﬁned to supportive care therapy suchMay 2016as ﬁlgrastim and ESA biosimilars, which, on
the whole, have been shown to be comparable in
efﬁcacy and safety to their originators.45 The clinical
success of these supportive care agents in oncology
invites the development of biosimilars for curative
therapy.
Institutions welcome the potential for signiﬁcant
reduction in costs with biosimilars as well as oncolo-
gists, many of whom report that drug costs feature in
their clinical decisions.46 Cost-effectiveness and estab-
lishment of best practice and ongoing postmarketing
surveillance have been researched in the routine
clinical management of the oncology patient. Large
observational studies (MONITOR-GCSF [Multi-level
Evaluation of Chemotherapy-induced Febrile Neutro-
penia Prophylaxis, Outcome, and Determinants with
Granulocyte-colony Stimulating Factor], NEXT, and
ORHEO [Epoetin Alfa Biosimilar in the Management
of Chemotherapy-Induced Symptomatic Anaemia in
Haematology and Oncology]) across European coun-
tries report long-term efﬁcacy and safety of the
biosimilars ﬁlgrastim and epoetin for febrile neutro-
penia or chemotherapy-induced anemia, respectively,
in real-world patients with cancer.47,48 The cost
reductions associated with biosimilar granulocyte
colony–stimulating factor have resulted in an increase
in access in most European markets (ranging from 2%
in Belgium to an almost 100% share of the accessible
market in Croatia, Czech Republic, Hungary, and
Romania)49; this may be a demonstration of the “real
value” of biosimilars.
Rheumatology
The inﬂiximab biosimilar has already been intro-
duced in some countries for rheumatic conditions. In
addition to ongoing studies on other anti–tumor
necrosis factor-α biosimilars (eg, adalimumab and
etanercept), several rituximab biosimilars are in ad-
vanced stages of development, and some are currently
undergoing evaluation in clinical trials of patients with
RA.50 Results from these studies, if positive, will
contribute to existing clinical data for inﬂiximab
biosimilars in RA.51 There remain, however,
pertinent and valid challenges to the introduction of
biosimilars in rheumatology, not least is the need for
additional disease-speciﬁc clinical trials and postmar-
keting surveillance data.52
As for other areas of medicine, rheumatologists’
awareness of biosimilars is lacking (when compared,1245
Clinical Therapeuticsfor example, with other biologic therapies), parti-
cularly among those physicians with less clinical
experience.53 Encouragingly, rheumatology experts
and organizations worldwide have taken a collective
stance to inform and guide physicians on the clinical
utility of biosimilars in rheumatic diseases.52,54 The
success of biosimilars, nevertheless, will lie with
practicing rheumatologists and their trust in the
evidence base for biosimilars in rheumatology.
Payer
Together with the clinical beneﬁts, the potential for
signiﬁcant cost savings and consequent greater patient
accessibility renders biosimilars an attractive proposi-
tion for payers.55 Possible cost advantages conferred
by competitive pricing (eg, as seen for generics) may
be tempered by such factors as the ability to
automatically substitute products.55
To date, evidence generally supports the cost
beneﬁts of biosimilars.49,56 As part of the ﬁrst scheme
operated by the London Procurement Programme in
the United Kingdom, a process was implemented to
rationalize the use of erythropoietin for chronic
kidney disease patients in South London in 2006 with
collaboration from renal centers and Primary Care
trusts (David Stead, personal communication). Specif-
ically, agreement was reached to repatriate a number
of patients to 1 of 4 centers where rational drug use
was initiated based on a tender that clearly indicatedTable III. Issues in biosimilar development process and
Process Issue
Substitution4,12 (of
originator for biosimilar
or between biosimilars)
Unintentional or automatic su
by pharmacists
Switching/
interchangeability5,58,*
Safety and efﬁcacy effects of sw
alternating to and from bio
and their reference product
Pharmacovigilance12 Confusion in naming for AE d
AE ¼ adverse event; INN ¼ international nonproprietary name.
1246which would/should be ﬁrst-line for new patients and
those who were switching treatment. This produced a
cost saving of several million GBP per year (David
Stead, personal communication) and has since been
replicated in other UK regions. In implementing such a
process for a biosimilar, there are important consid-
erations to take into account: assessing the current
market (who is prescribing the drug [general practi-
tioner or hospital]); whether it is possible to ration-
alize the range of products used; how to gain the best
price (usually in hospital) and whether health care
trusts can meet the potentially higher workload; and
ensuring a collaborative approach from all parties
concerned. Thus, with resolution of key issues such as
the lack of real-world cost and best practice data, the
prospect of cost advantages and greater patient access
works in favor of biosimilars from a payer
perspective.DISCUSSION AND CONCLUSIONS
Regulatory authorities have implemented guidelines
for the development and approval of biosimilars for
clinical use, but physicians have been largely unaware
of the nature of these processes.3 Physicians also need
to be aware of the monitoring routinely performed by
regulatory agencies to assess manufacturing changes
in biologics in order to ensure that such changes do
not lead to changes in the originator molecule.57 Theclinical practice.
Potential Solution
bstitution Regulatory measures to deﬁne automatic
substitution policies
itching or
similars
s
Studies investigating switching and/or
alternating between existing biologics
rug reports Appropriate measures to identify product
brand name and batch number
Regulatory bodies adopt and approve
risk-management plans to include
speciﬁcally focused postmarketing
studies
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compared with that stipulated for originators may
have given physicians cause for concern with respect
to the reliability of the evidence supporting the
approval of biosimilars.5 As summarized in Table III,
there remain gaps in the process that clinicians should
be aware of in order to effectively and safely prescribe
biosimilars, although the continuously evolving nature
of the biosimilar approval process will undoubtedly
resolve these issues in time. Additionally, it must be
noted that all biologics must manage nonidenticality,
not just biosimilars. This includes microheterogeneity
and batch-to-batch variability and potentially intended
and unintended drift due to manufacturing changes
over time. Because of the inherent variability of biologic
systems, biologics cannot be identical to themselves.
Therefore, the biosimilar must replicate the variability
of the biologic being copied. The rigorous nature of the
biosimilar development process reviewed here offers a
safeguard to clinicians who may have experienced some
uncertainty regarding the use of biosimilars in their
clinical practice.
In this article, multidisciplinary experts spanning
the ﬁelds of gastroenterology, nephrology, oncology,
and rheumatology and from a payer perspective
highlight a real potential for biosimilars to revolu-
tionize biologic therapy by increasing access to a
wider patient population across disciplines, but only
with appropriate implementation of postmarketing
strategies to monitor risk-beneﬁt proﬁles over the
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